Ten years of antisense inhibition of brain G-protein-coupled receptor function

Brain Research Reviews

Volumn 42, Issue 2, 2003, Pages 123-142

  Van Oekelen, Dirk ^a   Luyten, Walter H M L ^a   Leysen, Josée E ^a,b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Antisense; CNS; GPCR

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; ION CHANNEL; MESSENGER RNA; PHOSPHOROTHIOIC ACID;

BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; CORRELATION ANALYSIS; CORRELATION FUNCTION; DENSITY; GENE EXPRESSION; GENE REPRESSION; HUMAN; IN VIVO STUDY; MEDICAL LITERATURE; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REDUCTION; REVIEW;

EID: 0038327578     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(03)00153-X     Document Type: Review

References (220)

1. Adams J.U., Chen X., DeRiel J.K., Adler M.W., Liu-Chen L.Y. Intracerebroventricular treatment with an antisense oligodeoxynucleotide to k-opioid receptors inhibited k-agonist-induced analgesia in rats. Brain Res. 667:1994;129-132.
2. Agrawal S., Temsamani J., Tang J.Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA. 88:1991;7595-7599.
3. Akhtar S., Kole R., Juliano R.L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 49:1991;1793-1801.
4. Ambuhl P., Gyurko R., Phillips M.I. A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the angiotensin ATl receptor. Regul. Pept. 59:1995;171-182.
5. 2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat. Synapse. 26:1997;199-288.
6. Ballas Z.K., Rasmussen W.L., Krieg A.M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157:1996;1840-1845.
7. Beltinger C., Saragovi H.U., Smith R.M., LeSauteur L., Shah N., DeDionisio L., et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95:1995;1814-1823.
8. 1 receptor antisense infused in striatum of rats: actions on alcohol-induced locomotor impairment, blood alcohol and body temperature. Alcohol. 14:1997;617-621.
9. 2, Glu4] deltorphin antinociception by supraspinal, but not spinal, administration of an antisense oligodeoxynucleotide to an opioid d receptor. Life Sci. 55:1994;PL37-PL43.
10. Bilsky E.J., Bernstein R.N., Hruby V.J., Rothman R.B., Lai J., Porreca F. Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated 'knock-down' of opioid receptors in vivo. J. Pharmacol. Exp. Ther. 277:1996;491-501.
11. Bilsky E.J., Wang T., Lai J., Porreca F. Selective blockade of peripheral delta opioid agonist induced antinociception by intrathecal administration of delta receptor antisense oligonucleotide. Neurosci. Lett. 220:1996;155-158.
12. 2A receptors in brain. J. Phamacol. Exp. Ther. 299:2001;277-299.
13. Boiziau C., Kurfurst R., Cazenave C., Roig V., Thuong N.T., Toulme J.J. Inhibition of translation initiation by antisense oligonucleotides via an RNase-H independent mechanism. Nucleic Acids Res. 19:1991;1113-1119.
14. Brussaard A.B. Antisense oligonucleotides induce functional deletion of ligand gated ion channels in cultured neurons and brain explants. J. Neurosci. Methods. 71:1997;55-64.
15. Brysch W., Schlingensiepen K.L. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents. Cell. Mol. Neurobiol. 14:1994;557-568.
16. Campbell J.M., Bacon T.A., Wickstrom E. Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, sera and cerebrospinal fluid. J. Biochem. Biophys. Methods. 20:1990;259-267.
17. Cha X.Y., Xu H., Rice K.C., Porreca F., Lai J., Ananthan S., et al. Opioid peptide receptor studies. 1. Identification of a novel δ-opioid receptor binding site in rat brain membranes. Peptides. 16:1995;191-198.
18. Chavany C., Le Doan T., Couvreur P., Puisieux F., Hélène C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm. Res. 9:1992;441-449.
19. Chen X.H., Geller E.B., de Riel J.K., Liu-Chen L.Y., Adler M.W. Antisense oligonucleotides against μ- or κ-opioid receptors block agonist-induced body temperature changes in rats. Brain Res. 688:1995;237-241.
20. Chen X.H., Geller E.B., DeRiel J.K., Liu-Chen L.Y., Adler M.W. Antisense confirmation of μ- and κ-opioid receptor mediation of morphine's effects on body temperature in rats. Drug Alcohol Depend. 43:1996;119-124.
21. Cheung R.T.F., Cechetto D.F. Neuropeptide Y-Y1 receptor antisense oligonucleotide increases the infarct volume after middle cerebral artery occlusion in rats. Neuroscience. 98:2000;771-777.
22. Chiang M.Y., Chan H., Zounes M.A., Freier S.M., Lima W.F., Bennet C.F. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:1991;18162-18171.
23. Chien C.C., Brown G., Pan Y.X., Pasternak G.W. Blockade of U50,488H analgesia by antisense oligodeoxynucleotides to a kappa-opioid receptor. Eur. J. Pharmacol. 253:1994;R7-R8.
24. 7 receptors in the rat hypothalamus without alteration in exploratory behaviour or neuroendocrine function. J. Neurochem. 71:1998;1271-1279.
25. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J. Pharmacol. Exp. Ther. 267:1993;1181-1190.
26. Creese I., Tepper J.M. Antisense knockdown of brain dopamine receptors. Adv. Pharmacol. 42:1998;S17-S20.
27. Crooke S.T. Advances in understanding the pharmacological properties of antisense oligonucleotides. Adv. Pharmacol. 40:1997;1-37.
28. Crooke R.M., Graham M.J., Cooke M.E., Crooke S.T. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J. Pharmacol. Exp. Ther. 275:1995;462-473.
29. Crooke S.T., Graham M.J., Zuckerman J.E., Brooks D., Conklin B.S., Cummins L.L., et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:1996;923-937.
30. 1 receptor in the mouse. Brain Res. 864:2000;186-194.
31. 1 receptor in mice. Pharmacol. Biochem. Behav. 69:2001;251-259.
32. 1 antisense distinguishes receptors mediating angiotensin II actions in solitary tract nucleus. Hypertension. 37:2001;1292-1297.
33. Dorri F., Hampson D.R., Kaskys A., Wojtowicz J.M. Down-regulation of mGluR5 by antisense deoxynucleotides alters pharmacological responses to applications of ACPD in the rat hippocampus. Exp. Neurol. 147:1997;48-54.
34. Dubuc I., Sarret P., Labbé-Jullié C., Botto J.M., Honoré E., Bourdel E., et al. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci. 19:1999;503-510.
35. 2 receptor in the behavioral effects of imipramine - study with the use of antisense oligonucleotides. J. Physiol. Pharmacol. 51:2000;401-409.
36. 5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides. NeuroReport. 9:1998;1-5.
37. 3H]spiperone binding. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;342-350.
38. Eckstein F. Nucleoside phosphorothioates. Annu. Rev. Biochem. 54:1985;367-402.
39. Edsall S.A., Knapp R.J., Vanderah T.W., Roeske W.R., Consroe P., Yamamura H.I. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. NeuroReport. 7:1996;593-596.
40. 1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br. J. Pharmacol. 126:1999;1769-1776.
41. Erlinge D., Edvinsson L., Brunkwall J., Yee F., Wahlestedt C. Human neuropeptide Y Y1 receptor antisense oligodeoxynucleotide specifically inhibits neuropeptide Y-evoked vasoconstriction. Eur. J. Pharmacol. 240:1993;77-80.
42. Fakler B., Herlitze S., Amthor B., Zenner H.P., Ruppersberg J.P. Short antisense oligonucleotide-mediated inhibition is strongly dependent on oligo length and concentration but almost independent of location of the target sequence. J. Biol. Chem. 269:1994;16187-16194.
43. Farrel C.L., Bready J.V., Kaufman S.A., Qian Y., Burgess T.L. The uptake and distribution of phosphorothioate oligonucleotides into vascular smooth muscle cells in vitro and in rabbit arteries. Antisense Res. Dev. 5:1995;175-183.
44. 5 receptors in nucleus accumbens contribute to the detection of cocaine in rats. J. Neurosci. 20:2000;1-4.
45. Foo H., Helmstetter F.J. Expression of antinociception in response to a signal for shock is blocked after selective downregulation of μ-opioid receptors in the rostal ventromedial medulla. Mol. Brain Res. 76:2000;282-288.
46. Fraser G.L., Homgren J., Clarke P.B.S., Wahlestedt C. Antisense inhibition of δ-opioid receptor gene function in vivo by peptide nucleic acids. Am. Soc. Pharmacol. Exp. Ther. 57:2000;725-731.
47. 2,5]-enkephalin (DPDPE) is pharmacologically distinct from that to other δ-agonists in the rat. J. Pharmacol. Exp. Ther. 295:2000;1135-1141.
48. S.M. Freier, Hybridization: Considerations affecting antisense drugs, in: S.T. Crooke, B. Lebleu (Eds.), Antisense Research and Applications, CRC Press, Boca Raton, Florida, 1993, p. 67.
49. 5, but not progestin receptor, antagonist and anti-sense oligonucleotide infusions to the ventral tegmental area of cycling rats and hamsters attenuate lodosis. Behav. Brain Res. 103:1999;23-34.
50. Galli R.L., Fine R.E., Thorpe B.C., Hale B.S., Lieberman H.R. Antisense oligonucleotide sequences targeting the muscarinic type 2 acetylcholine receptor enhance performance in the morris water maze. Int. J. Neuroscience. 103:2000;53-68.
51. Gao W.L., Han F.S., Storm C., Egan W., Cheng Y.C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerises and RNAse H: implications for antisense technology. Mol. Pharmacol. 41:1992;223-229.
52. 1 receptors induces transient anterograde amnesia in mice. Neuropharmacology. 38:1999;339-348.
53. 2+. Biochem. Biophys. Res. Commun. 181:1991;915-920.
54. Giles R.V., Spiller D.G., Tidd D.M. Chimeric oligonucleotide analogues: enhanced cell uptake of structures which direct ribonuclease H with high specificity. Anticancer Drug Des. 8:1993;33-51.
55. Gillardon F., Vogel J., Hein S., Zimmermann M., Uhlmann E. Inhibition of carrageenan-induced spinal c-Fos activation by systemically administered c-fos antisense oligodeoxynucleotides may be facilitated by local opening of the blood-spinal cord barrier. J. Neurosci. Res. 47:1997;582-589.
56. Greenwood R.S., Zheng F., McHugh R., Meeker R. Inhibition of hippocampal kindling by metabotropic glutamate receptor antisense oligonucleotides. Mol. Cell. Neurosci. 16:2000;233-243.
57. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it trom low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
58. 1 receptor mRNA and angiotensinogen mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenic origin. Regul. Pept. 49:1993;167-174.
59. 1 angiotensin receptor mRNA in spontaneously hypertensive rats. Am. J. Hypertens. 10:1997;56S-62S.
60. 2 dopamine receptro antisense increases the activity and mNRA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in mouse brain. Neurosci. Lett. 217:1996;105-108.
61. 6 receptors. Neuropsychopharmacology. 21:1999;68S-76S.
62. Hawley P., Gibson I. Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev. 6:1996;185-195.
63. Heilig M. Antisense inhibition of neuropeptide Y(NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Reg. Peptides. 59:1995;201-205.
64. 2, receptors mediate anxiogenic-like behavior. Reg. Peptides. 71:1997;15-21.
65. Hélène C., Toulmé J.J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim. Biophys. Acta. 1049:1990;99-125.
66. Hersi A.I., Kitaichi K., Srivastava L.K., Gaudreau P., Quirion R. Dopamine D-5 receptor modulates hippocampal acetylcholine release. Mol. Brain Res. 76:2000;336-340.
67. Ho S.P., Takahashi L.K., Livanov V., Spencer K., Lesher T., Maciag C., et al. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Mol. Brain. Res. 89:2001;29-40.
68. Hoke G.D., Draper K., Freier S.M., Gonzalez C., Driver V.B., Zounes M.C., et al. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridisation and antiviral efficacy versus herpes simplex virus infection. Nucl. Acids Res. 19:1991;5743-5748.
69. Holland K.L., Popper P., Micevych P.E. Infusion of CCK-A receptor mRNA antisense oligodeoxynucleotide inhibits lordosis behavior. Physiol. Behav. 62:1997;537-543.
70. 2-adrenoceptor. J. Auton. Pharmacol. 19:1999;311-320.
71. Idänpään-Heikkilä J., Rauhala P., Männistö P. MU- and delta-opioid receptor antisense oligodeoxy-nucleotides antagonize morphine-induced growth hormone secretion in rats. Eur. J. Pharmacol. 284:1995;227-230.
72. Iversen P.L. In vivo studies with phosphorothioate oligonucleotides pharmacokinetics prologue. Anticancer Drug Des. 6:1991;531-538.
73. 1-adrenergic receptor antagonists. Toxicol. Appl. Pharmacol. 160:1999;289-296.
74. Iversen P.L., Zhu S., Meyer A., Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. 2:1992;211-222.
75. Iyer S.N., Lu D., Katovich M.J., Raizada M.K. Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotenin type 1 receptor antisense. Proc. Natl. Acad. Sci. USA. 93:1996;9960-9965.
76. Kagiyama S., Varela A., Phillips M.I., Galli S.M. Antisense inhibition of brain renin-angiotensin system decreased blood pressure in chronic 2-kidney, 1 clip hypertensive rats. Hypertension. 37:2001;371-375.
77. 1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventriculary administered antisense oligodeoxynucleotide. Naunyn-Schmiedeberg's Arch. Pharmacol. 360:1999;420-427.
78. Kest B., Lee C.E., McLemore G.L., Inturrisi C.E. An antisense oligodeoxynucleotide to the delta-opioid (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brian Res. Bull. 39:1996;185-188.
79. Kest B., Lee C.E., Jeffrey S.M., Inturrisi C.E. Blockade of morphine supersensitivity by an antisense oligodeoxynucleotide targeting the delta opioid receptor (DOR-1). Life Sci. 60:1997;155-159.
80. 2A receptor binding and function in rat frontal cortex. Neuropharmacology. 38:1999;1421-1430.
81. Khasar S.G., Gold M.S., Dastmalchi S., Levine J.D. Selective attenuation of μ-opioid receptor-mediated effects in rat sensory neurons by intrathecal administration of antisense oligodeoxynucleotides. Neurosci. Lett. 218:1996;17-20.
82. King M., Chang A., Pasternak G.W. Functional blockade of opioid analgesia by orphanin FQ/Nociceptin. Biochem. Pharmcacol. 55:1998;1537-1540.
83. 1 receptor. Eur. J. Pharmacol. 331:1997;5-6.
84. Krieg A.M., Stein C.A. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5:1995;241.
85. Lacks S.A. Deoxyribonuclease I in mammalian tissues. Specificity of inhibition by actin. J. Biol. Chem. 256:1981;2644-2648.
86. 1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J. Neurosci. 15:1995;4250-4258.
87. Landgraf R., Naruo T., Vecsernyes M., Neumann I. Neuroendocrine and behavioral effects of antisense oligonucleotides. Eur. J. Endocrinol. 151:1997;333-340.
88. Lanneau C., Bluet-Pajot M.T., Zizzari P., Csaba Z., Dournaud P., Helboe L., et al. Involvement of the sst1 somatostatin receptor subtype in the intrahypothalamic neuronal network regulating growth hormone secretion: an in vitro and in vivo antisense study. Endocrinology. 141:2000;967-979.
89. Lee C.E., Kest B., Jenab S., Inturrisi C.E. Effect of supraspinal antisense oligodeoxynucleotide treatment on δ-opioid receptor mRNA levels in mice. Mol. Brain Res. 48:1997;17-22.
90. Leventhal L., Cole J.L., Rossi G.C., Pan Y.X., Pasternak G.W., Bodnar R.J. Antisense oligodeoxynucleotides against the MOR-1 clone alter weight and ingestive responses in rats. Brain Res. 719:1996;78-84.
91. Li B., Hughes J.A., Phillips M.I. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem. Int. 31:1997;393-403.
92. Lima W.F., Crooke S.T. Binding affinity and specificity of Escherichia coli RNase H1: impact on the kinetics of catalysis of antisense oligonucleotide-RNA hybrids. Biochemistry. 36:1997;390-398.
93. Liu P.K., Salminen A., He Y.Y., Jiang M.H., Xue J.J., Liu J.S., Hsu C.Y. Suppression of ischemia-induced fos expression and AP-1 activity by an antisense oligodeoxynucleotide to c-fos mRNA. Ann. Neurol. 36:1994;566-576.
94. Loke S.L., Stein C.A., Zhang X.H., Mori K., Nakanishi M., Subasinghe C., et al. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA. 86:1989;3474-3478.
95. Lopez-Valpuesta F.J., Nyce J.W., Myers R.D. NPY-Y1 receptor antisense injected centrally in rats causes hyperthermia and feeding. NeuroReport. 7:1996;2781-2784.
96. Lopez-Valpuesta F.J., Nyce J.W., Griffin-Bigs T.A., Ice J.C., Myers R.D. Antisense to NPY-Y1 demonstrates that Y1 receptors in the hypothalamus underlie NPY hypothermia and feeding in rats. Proc. R. Soc. Lond. 263:1996;81-886.
97. Lu D., Raizada M.K. Delivery of angiotensin II type 1 receptor antisense inhibits angiotens action in neurons form hypertensive rat brain. Proc. Natl. Acad. Sci. USA. 92:1995;2914-2918.
98. 2C-adrenoceptors in rat striatum following antisense oligodeoxynucleotide infusion. Mol. Brain Res. 47:1997;267-274.
99. 2C-adrenoceptors mediate inhibition of forskolin-stimulated cAMP production in rat striatum. Mol. Brain Res. 52:1997;228-234.
100. Maltese J.Y., Sharma H.W., Vassilev L., Narayanan F. Sequence context of antisense RelA/NF-κB phosphorotoates determines specificity. Nucleic Acid. Res. 23:1995;1146-1151.
101. Martinez V., Wu S.V., Taché Y. Intracisternal antisense oligodeoxynucleotides to the thryrotropin-releasing hormone receptor blocked vagal-dependent stimulation of gastric emptying induced by acute cold in rats. Endocrinology. 139:1998;3730-3735.
102. Martinez V., Rivier J., Coy D., Taché Y. Intracisternal injection of somatostatin receptor 5-preferring agonists induces a vagal cholinergic stimulation of gastric emptying in rats. J. Pharmacol. Exp. Ther. 293:2000;1099-1105.
103. Martinez V., Wang L., Taché Y. Central THR receptor 1 antisense blocks cold-induced gastric emptying but not brain c-fos induction. Peptides. 22:2001;81-90.
104. Matsumoto M., Togaschi H., Mori K., Ueno K.I., Miyamoto A., Yoshioka M. Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur. J. Pharmacol. 383:1999;39-48.
105. McCarty M.M., Kleopoulos S.P., Mobbs C.V., Pfaff D.W. Infusion of antisense oligodeoxynucleotides to the oxytocin receptor in the ventromedial hypothalamus reduces estrogen induced sexual receptivity and oxytocin receptor binding in the female rat. Neuroendocrinology. 59:1994;432-440.
106. Meeker R., LeGrand G., Ramirez J., Smith T., Shih Y. Antisense vasopressin oligonucleotides: uptake, turnover, distribution, toxicity and behavioural effects. J. Neuroendocrinol. 7:1995;419-428.
107. 2 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. NeuroReport. 10:1999;3131-3136.
108. Meng H., Wielbo D., Gyurko R., Phillips M.I. Antisense oligonucleotide to AT, receptor mRNA inhibits central angiotensin induced thirst and vasopressin. Regul. Pept. 54:1994;543-551.
109. Mirabelli C.K., Bennett C.F., Anderson K., Crooke S.T. In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des. 6:1991;647-661.
110. 2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat. J. Clin. Invest. 98:1996;1076-1080.
111. 2] deltorphin II-induced locomotor hyperactivity. Life Sci. 59:1996;69-73.
112. Morris K., Lucion V. Antisense oligonucleotides in the study of neuroendocrine systems. J. Neuroendocrinol. 7:1995;493-500.
113. Moulds C., Lewis J.G., Froehler B.C., Grant D., Huang T., Milligan J.F., et al. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry. 34:1995;5044-5053.
114. Murray J.A.H., Crockett N. Antisense techniques: an overview. Murray J.A. Antisense RNA and DNA. 1992;1-49 Wiley-Liss, NY.
115. 2 receptor antisense oligonucleotides injected in nucleus accumbens suppress high alcohol intake in genetic drinking HEP rats. Alcohol. 16:1999;225-233.
116. Nakai D., Seita T., Terasaki T., Iwasa S., Shoji Y., Mizushima Y., et al. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15. J. Pharmacol. Exp. Ther. 278:1996;1362-1372.
117. 2-opioid receptor agonist in the mouse spinal cord. Br. J. Pharmacol. 120:1997;587-592.
118. Negri L., Broccardo M., Lattanzi R., Melchiorri P. Effects of antisense oligonucleotides on brain delta-opioid receptor density and on SNC80-induced locomotor stimulation and colonic transit inhibition in rats. Br. J. Pharmacol. 128:1999;1554-1560.
119. Negri L., Lattanzi R., Borsodi A., Toth G., Salvatori S. Differention knockdown of δ-opioid receptor receptor subtypes in the rat brain by antisense oligodeoxynucleotides targeting mRNA. Antisense Nucleic. Acid Drug Dev. 9:1999;203-211.
120. Ni Q., Xu H., Partilla J.S., Rice K.C., Matecka D., Calderon S.N., et al. Opioid peptide receptor studies. 9. Identification of a novel non-μ- non-δ-like opioid peptide binding site in rat brain. Peptides. 19:1998;1079-1090.
121. Nicot A., Pfaff D.W. Antisense oligonucleotides as specific tools for studying neuroendocrine and behavioral functions: some prospects and problems. J. Neurosci. Methods. 71:1997;45-53.
122. 3 receptor antisense influences dopamine synthesis in rat brain. Neuroreport. 6:1995;573-576.
123. 2-adrenoceptors and blood pressure regulation in the rat. Eur. J. Pharmacol. 278:1995;183-185.
124. O-Keefe S.J., Wolfes H., Kiessling A.A., Cooper G.M. Microinjection of antisense c-mos oligonucleotides prevents meiosis II in the maturing mouse egg. Proc. Natl. Acad. Sci. USA. 86:1989;7038-7042.
125. Ogawa S., Brown H.E., Okano H.J., Pfaff D.W. Cellular uptake of intracerebrally administered oligodeoxynucleotides in mouse brain. Reg. Peptides. 59:1995;143-149.
126. Ogo H., Hirai Y., Miki S., Nishio H., Akiyama M., Nakata Y. Modulation of substance P/neurokinin-1 receptor in human astrocytoma cells by antisense oligodeoxynucleotides. Gen. Pharmacol. 25:1994;1131-1135.
127. Oguro K., Oguro N., Kojima T., Grooms S.Y., Calderone A., Zheng X., et al. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. J. Neurosci. 19:1999;9218-9227.
128. Otano A., Frechilla D., Cobreros A., Cruz-Orive L.M., Insausti A., Insausti R., et al. Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience. 92:1999;1001-1009.
129. Owens M.J., Mulchahey J.J., Kaskow J.W., Plotsky P.M., Nemeroff C.B. Exposure to an antisense oligonucleotide decreases corticotropin-releasing factor receptor binding in rat pituitary cultures. J. Neurochem. 64:1995;2358-2361.
130. 3-related opioid receptor. Mol. Pharmacol. 47:1995;1180-1188.
131. 2A receptor antisense oligodeoxynucleotides. Psychiatry Res. 63:1996;197-203.
132. Pasternak G.W., Standifer K.M. Mapping of opioid receptors using antisense oligodeoxynucleotides: correlating their molecular biology and pharmacology. Trends Pharmacol. Sci. 16:1995;344-350.
133. 1-receptor mRNA in brain and blood. Hypertension. 31:1998;1317-1323.
134. Perez J.R., Li Y., Stein C.A., Majumder S., van Oorschot A., Narayanan R. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA. 91:1994;5957-5961.
135. Peyman A., Helsberg M., Kretzschmar G., Mag M., Grabley S., Uhlmann E. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol. Chem. Hoppe Seyler. 376:1995;195-198.
136. 1 receptor antisense oligodeoxynucleotide blocks ethanol-induced motor incoordination. Eur. J. Pharmacol. 323:1997;5-7.
137. 1 receptor oligodeoxynucleotide decreases adenosine A1 receptors in the rat striatum and cortex. Mol. Brain Res. 72:1999;226-230.
138. Phillips M.L., Wielbo D., Gyurko R. Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genes. Kidney Int. 46:1994;1554-1556.
139. 1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensive rats. Life Sci. 66:2000;2091-2099.
140. Pierga J.Y., Magdelenat H. Applications of antisense oligonucleotides in oncology. Cell. Mol. Biol. 40:1994;237-261.
141. Pinto W., Battaglia G. Comparative recovery kinetics of 5-hydroxytryptamine 1A, 1B, and 2A receptor subtypes in rat cortex after receptor inactivation: evidence for differences in receptor production and degradation. Am. Soc. Pharmacol. Exp. Ther. 46:1994;1111-1119.
142. 2 dopamine receptors. Mol. Pharmacol. 48:1995;730-737.
143. Rajakumar N., Laurier L., Niznik H.B., Stoessl A.J. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat. Synapse. 26:1997;199-208.
144. Reed J.C., Stein C., Subasinghe C., Haldar S., Croce C.M., Yum S., Cohen J. Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 50:1990;6565-6570.
145. Rossi G., Pan Y.X., Cheng J., Pasternak G.W. Blockade of morphine analgesia by an antisense oligodeoxynucleotide against the mu receptor. Life Sci. 54:1994;375-379.
146. Rossi G.C., Standifer K.M., Pasternak G.W. Differential blockade of morphine and morphine-6β-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein α subunits in rats. Neurosci. Lett. 198:1995;99-102.
147. Rossi G.C., Leventhal L., Pan Y.X., Cole J., Su W., Bodnar R.J., Pasternak G.W. Antisense mapping of MOR-1 in rats: Distinguishing between
148. 1 receptor antisense oligonucleotides inhibits the behavioral actions of angiotensin II. J. Neurochem. 62:1994;2053-2056.
149. 1) receptor antisense oligonucleotides attenuate thirst in the rat. Reg. Peptides. 59:1995;183-192.
150. Sánchez-Blázquez P., García-España A., Garzón. Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. J. Pharmacol. Exp. Ther. 280:1997;1423-1431.
151. 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol. Pharmacol. 45:1994;932-943.
152. 1A receptor expression in the rat brain by antisense RNA and oligodeoxynucleotides. Neurosci. Lett. 259:1999;191-195.
153. Sawai Y., Sawasaki Y., Tsukada K. Ribonuclease H activity in developing rat brain. Life Sci. 21:1977;1351-1356.
154. 2A receptor expression by an antisense oligodeoxynucleotide. J. Neurochem. 71:1998;1457-1463.
155. 1 dopamine receptor-mediated grooming behavior. Pharmacol. Biochem. Behav. 63:1999;279-284.
156. Schaffhauser A.O., Stricker-Krongrad A., Hofbauer K.G. NPY Y5 receptor subtype. Methods Mol. Biol. 153:2000;129-150.
157. Schaffhauser A.O., Stricker-Kongrad A., Brunner L., Cumin F., Gerald C., Whitebread S., et al. Inhibition of food intake by neuropeptide Y Y5 receptor antisense oligodeoxynucleotides. Diabetes. 46:1997;1792-1798.
158. Shah S., Duttaroy A., Chen B.T., Carroll J., Yoburn B.C. The effect of μ-opioid receptor antisense on morphine potency and antagonist-induced supersensitivity and receptor upregulation. Brain Res. Bull. 42:1997;479-484.
159. Shishkina G.T., Kalinina T.S., Sournina N.Y., Dygalo N.N. Effects of antisense to the α2A-adrenoceptors administered into the region of the locus ceruleus on behaviors in plus-maze and sexual behavior tests in sham-operated and castrated male rats. J. Neurosci. 21:2001;726-731.
160. Shoji Y., Akhtar S., Periasamy A., Herman B., Juliano R.L. Mechanism of cellular uptake of modified oligodeoxynucleotides containing melhylphosphonate linkages. Nucl. Acids Res. 19:1991;5543-5550.
161. 2A receptor induces an antidepressant-like effect in mice. Mol. Pharmacol. 52:1997;1052-1063.
162. 2 autoreceptors in the motor actions of cocaine. Mol. Pharmacol. 46:1994;51-57.
163. 6 expression in the rat: functional studies using antisense oligonucleotides. Behav. Brain Res. 73:1996;245-248.
164. 2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. NeuroReport. 9:1998;1601-1606.
165. Sommer W., Bjelke B., Ganten D., Fuxe K. Antisense oligonucleotide to c-fos induces ipsilateral rotational behaviour to D-amphetamine. Neuroreport. 5:1993;277-280.
166. Sommer W., Cui X., Erdmann B., Wiklund L., Bricca G., Heilig M., et al. The spread and uptake pattern of intracerebrally administered oligonucleotides in nerve and glial cell populations of the rat brain. Antisense Nucleic Acid Drug Dev. 8:1998;75-85.
167. Spampinato S., Canossa M., Carboni L., Campana G., Leanza G., Ferri S. Inhibition of proopiomelanocortin expression by an oligodeoxynucleotide complementary to beta-endorphin mRNA. Proc. Natl. Acad. Sci. USA. 91:1994;8072-8076.
168. Standifer K.M., Chien C.C., Wahlestedt C., Brown G.P., Pasternak G. Selective loss of δ opioid analgesia and binding by antisense oligodeoxynucleotides to a δ opioid receptor. Neuron. 12:1994;805-810.
169. Standifer K.M., Jenab S., Su W., Chien C.C., Pan Y.X., Inturrisi C.E., Pasternak G.W. Antisense oligodeoxynucleotides to the cloned δ receptor. DOR-l: Uptake, stability and regulation of gene expression. J. Neurochem. 65:1995;1981-1987.
170. Standifer K.M., Jenab S., Su W., Chien C.C., Pan Y.X., Inturrisi C.E., et al. Antisense oligodeoxynucleotides to the cloned delta receptor DOR-1: uptake, stability, and regulation of gene expression. J. Neurochem. 65:1995;1981-1987.
171. Stein C.A. Phosphorothioate antisense oligodeoxynucleotides. Questions of specificity. Trends Biotechnol. 14:1996;147-149.
172. Stein C.A., Cheng Y.C. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science. 261:1993;1004-1012.
173. Stein C.A., Neckers L.M., Nair B.C., Mumbauer S., Hoke G., Pal R. Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J. Acquir. Immune Defic. Syndr. 4:1991;686-693.
174. Stein C.A., Subasinghe C., Shinozuka K., Cohen J.S. Physicochemical properties of phosphorothioate oligodeoxynucleotdies. Nucl. Acids Res. 16:1988;3209-3291.
175. Stephenson M.L., Zamecnik P.C. Inhibition of rous sarcoma viral RNA translation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75:1978;285-288.
176. Suzuki T., Tsuji M., Ikeda H., Misawa M., Narita M., Tseng L.F. Antisense oligodeoxynucleotide to δ opioid receptors blocks cocaine-induced place preference in mice. Life Sci. 60:1997;283-288.
177. Szklarczyk A., Kaczmarek L. Antisense oligodeoxyribonucleotides: stability and distribution after intracerebral injection into rat brain. J. Neurosci. Methods. 60:1995;181-187.
178. Szklarczyk A., Kaczmarek L. Pharmacokinetics of antisense analogues in the central nervous system. Neurochem. Int. 31:1997;413-423.
179. Tavitian B., Terrazzino S., Kuhnast B., Marzabal S., Stettler O., Dolle F., et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat. Med. 4:1998;467-471.
180. Temsamani J., Guinot P. Antisense oligonucleotides: a new therapeutic approach. Biotechnol. Appl. Biochem. 26:1997;65-71.
181. Temsamani J., Kubert M., Tang J., Padmapriya A., Agrawal S. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. 4:1994;35-42.
182. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown. J. Neurosci. 17:1997;2519-2530.
183. Thomas K.R., Capecchi M.R. Targeted disruption of the murine int-1 proto-oncogene resulting in severe abnormalities in midbrain and cerebellar development. Nature. 346:1990;847-850.
184. Toulme E. Artificial Regulation of Gene Expression by Complementary Oligonucleotides - an Overview. In Antisense RNA and DNA. 1992;175-194 Wiley Liss, New York.
185. 3 receptor antisense reduces neuropeptide mRNA levels in rat nucleus accumbens. NeuroReport. 8:1997;3901-3905.
186. 3 receptor functions in rat forebrain. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 22:1998;857-882.
187. 3 receptor antisense administration reduces basal c-fos and NGFI-B mRNA levels in the rat forebrain. Synapse. 32:1999;51-57.
188. Tseng L.F., Collins K.A. Antisense oligodeoxynucleotide to a δ-opioid receptor given intrathecally blocks i.c.v. administered β-endorphin-induced antinociception. Life Sci. 55:1994;127-131.
189. Tseng L.F., Collins K.A., Kampine J.P. Antisense oligodeoxynucleotide to a δ-opioid receptor selectively blocks the spinal antinociception induced by δ-, but not μ- or κ-opioid receptor agonists in the mouse. Eur. J. Pharmacol. 258:1994;1-3.
190. Tseng L.F., Narita M., Kampine J.P. Pretreatment with β-endorphin facilitates the attenuation of δ-opioid receptor-mediated antinociception caused by δ-opioid receptor antisense oligodeoxynucleotide. Eur. J. Pharmacol. 287:1995;169-172.
191. 2A receptors using antisense oligonucleotides, J. Neurochem. (in press).
192. 1A receptor function in a rodent model of tardive dyskinesia. Neuroscience. 101:2000;629-635.
193. 1A receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. Neuroscience. 98:2000;61-67.
194. Wagner R.W., Matteucci M.D., Lewis J.G., Gutierrez A.J., Moulds C., Froehler B.C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 260:1993;1510-1513.
195. Wahlestedt C., Pich E.M., Koob G.F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 259:1993;528-531.
196. Walder R.J., Walder J.A. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 85:1988;5011-5017.
197. Wang H.Q., Kampine J.P., Tseng L.F. Antisense oligodeoxynucleotide to a δ-opioid receptor messenger RNA selectively blocks the antinociception induced by intracerebroventriculary administered δ- but not μ-, ε- or κ-opioid receptor agonists in the mouse. Neuroscience. 75:1996;445-452.
198. Weiss B., Zhang S.P., Zhou L.W. Antisense strategies in dopamine receptor pharmacology. Life Sci. 7:1997;433-455.
199. 2 messenger RNA. Neuroscience. 55:1993;607-612.
200. Whitesell L., Geselowitz D., Chavany C., Fahmy B., Walbridge S., Alger J.R., et al. Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc. Natl. Acad. Sci. USA. 90:1993;4665-4669.
201. Whitesell L., Liu X., Bagatell R. Inhibition of oncogene expression using vector-generated RNA antisense. Methods. 18:1999;296-303.
202. Wickstrom E. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods. 13:1986;97-102.
203. Woolf T.M., Melton D.A., Jennings C.G.B. Specificity of antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;7305-7309.
204. Wright R.C., Ingenito A.J. Hippocampal administration of kappa-opioid receptor antisense exacerbates isolation-induced hypertension. Neuropeptides. 34:2000;357-360.
205. Wright R.C., McConnaughey M.M., Phan T.A., Ingenito A.J. κ-Opioid receptor antisense oligonucleotide injected into rat hippocampus causes hypertension. Eur. J. Pharmacol. 377:1999;57-61.
206. Yabukov L.A., Deeva E.A., Zaytova V.F., Ivanova E.M., Ryte A.S., Yurchenko L.V., et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA. 86:1989;6454-6458.
207. Yaida Y., Nowak T.S. Distribution of phosphodiester and phosphorothioate oligonucleotides in rat brain after intraventricular and intrahippocampal administration determined by in situ hybridization. Reg. Peptides. 59:1995;193-199.
208. Yee F., Ericson H., Reis D.J., Wahlestedt C. Cellular uptake of intracerebroventricularly administered biotin- or digoxigenin-labeled antisense oligodeoxynucleotides in the rat. Cell. Mol. Neurobiol. 14:1994;475-486.
209. Yeomans J.S., Takeuchi J., Baptista M., Flynn D.D., Lepik K., Nobrega J. Brain-stimulation reward thresholds raised by an antisense oligonucleotide for the M5 muscarinic receptor infused near dopamine cells. J. Neurosci. 20:2000;8861-8867.
210. Yoshikawa M., Yokogami K., Kitamura K., Kobayashi T., Kanai M., Taniguchi T., et al. Time course of changes in μ-opioid receptor mRNA levels in the periaqueductal gray of rat brain by a single or repeated injections of antisense oligodeoxynucleotides. Jpn. J. Pharmacol. 81:1999;209-215.
211. 6 receptor subtype in the rat brain. Life Sci. 62:1998;1473-1477.
212. Zamenick P.C., Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 75:1978;280-284.
213. Zang Z., Florijn W., Creese I. Reduction in muscarinic receptors by antisense oligodeoxynucleotide. Biochem. Pharmacol. 48:1994;225-228.
214. 2 receptors: behavioral correlates. Neurosci. Lett. 161:1993;223-226.
215. 1 dopamine receptor-mediated behaviors in normal mice and in mice lesioned with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 271:1994;1462-1470.
216. Zhang R., Lu Z., Zhang X., Zhao H., Diasio R.B., Liu T., et al. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin. Chem. 41:1995;836-843.
217. 2 dopamine receptor antisense oligodeoxynucleotide in mouse brain. J. Mol. Neurosci. 7:1996;13-28.
218. 1-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation. 101:2000;682-688.
219. 2 dopamine receptors in normal mice and in mice lesioned with 6-hydroxydopamine. Neurochim. Int. 29:1996;583-595.
220. 2 dopamine receptors in mouse striatum. J. Pharmacol. Expl. Ther. 268:1994;1015-1023.